July 29, 2013

FDA Clears Teleflex Arrow GPSCath in Higher Rated Burst Pressure and 80-cm Lengths

July 30, 2013—Teleflex Incorporated (Limerick, PA) announced that its subsidiary Hotspur Technologies, Inc. (Mountain View, CA), which Teleflex acquired in June 2012, received US Food and Drug Administration 510(k) clearance to market the company's Arrow GPSCath balloon dilatation catheters in higher rated burst pressure and 80-cm lengths.

According to Teleflex, the Arrow GPSCath catheter is a dual-functional balloon dilatation catheter that combines angioplasty and the company's VisioValve injection system. This combination enables physicians to perform high-pressure angioplasty and inject physician-specified fluids, such as contrast, while maintaining the guidewire position. These devices enable multiple vascular procedures to be performed with one dual-function catheter, potentially reducing procedure time and expense for both patients and medical professionals, the company stated.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

July 29, 2013

FDA Clears Teleflex Arrow GPSCath in Higher Rated Burst Pressure and 80-cm Lengths

Current Issue

Keep In Touch